Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN SODIUM versus UNIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN SODIUM versus UNIPEN.
AMPICILLIN SODIUM vs UNIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
1-2 g IV/IM every 4-6 hours for serious infections; maximum 12 g/day.
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
None Documented
None Documented
Terminal elimination half-life ~1 hour in healthy adults; prolonged to 2–5 hours in renal impairment (CrCl <10 mL/min) and up to 7–20 hours in anuria; neonatal half-life 2–4 hours.
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Approximately 90% renal excretion via tubular secretion and glomerular filtration; small biliary excretion (<10%); fecal elimination negligible.
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic